Print

Fedora Pharmaceuticals Inc. Appoints Thomas R. Parr, Ph.D., Chief Scientific Officer  
9/5/2012 9:18:35 AM

EDMONTON, Alberta, Sept. 5, 2012 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. today announced the appointment of Thomas Parr, Ph.D. to the newly created role of chief scientific officer. Dr. Parr was most recently chief scientific officer at Targanta Therapeutics, where he was instrumental in the development of oritavancin, a lipoglycopeptide for the treatment of Gram-positive bacterial infections.
//-->